BIEL Becomes The Story Stock for 2026 @ PPS = .003!
This would be a 3,000% gain (from .0001 on Oct. 9, 2025) and exceed the PPS increase for Apple, Amazon, Netflix, Microsoft, Google, etc., for the past 10 years. We're already 13% of the way there. This will generate a huge amount of FREE PUBLICITY for BIEL/Electrome that would otherwise cost millions of dollars, launching world-wide sales. Big money will be knocking at the door, begging to buy in (MAKE THEM BUY SHARES ON THE OPEN MARKET INSTEAD!).
BIEL Will Become the First Public-Market Gateway Into AI-Driven Bioelectric Medicine
A Venture-Scale Opportunity With Public-Market Leverage
BIEL stands at the edge of a valuation supercycle — a moment where narrative, technology, and timing converge. In the same way Amazon, Netflix, Apple, and Nvidia transformed from overlooked microcaps into generational winners, BIEL now sits at the threshold of its own quantum leap. But unlike those giants, BIEL’s inflection point could unfold in weeks, not decades.
Public investors almost never gain early access to AI-platform upside.
BIEL + Electrome change that — and a rising BIEL share price amplifies everything: capital access, partnership leverage, and media visibility.
At a moment when AI narratives alone have minted billionaires, a fast-appreciating stock can turn BIEL from an overlooked microcap into the story stock of 2026, attracting institutional attention, analyst coverage, and nonstop financial-press momentum.
FDA deregulation of non-medical wearable data has recreated the same conditions that allowed early AI giants to explode in value — and the market loves that storyline.
The Core Thesis
BIEL has the hardware.
Electrome has the AI.
The new vagus-nerve patent provides the defensible therapeutic target.
The leadership team provides the execution engine.
Together, they form a platform-level company — not a device company — and a rising share price strengthens their ability to scale, recruit, and negotiate from a position of strength.
The Patent That Raises the Valuation Ceiling
Utility Patent Application 18/667,971 — Non-Invasive Vagus Nerve Stimulation (VNS)
Key Value Drivers
Non-invasive VNS using PEMF — no implants, no surgery.
Targets chronic inflammation affecting over one-third of Americans.
Applicable to arthritis, depression, diabetes, cardiovascular issues, autoimmune disorders.
Built on BIEL’s already-cleared PEMF platform — the fastest path to commercialization.
Invented by Martinez, McLeod, and Staelin — engineering + commercialization pedigree.
A rising stock price increases the perceived value of this IP, strengthens licensing leverage, and attracts strategic partners who follow momentum.
Why This Matters to Investors
VNS is one of the most valuable neuromodulation categories in medicine.
Existing players rely on implants — high cost, high friction, limited scale.
A non-invasive, wearable VNS device is a category-defining product with multi-billion-dollar potential.
And if the stock begins to move, financial media will spotlight BIEL as the first public-market play on AI-driven VNS — a narrative Wall Street loves.
How the Patent Supercharges the AI Narrative
To become an AI platform, BIEL needed four pieces:
A brain — Electrome
A story — Ken Mayer
A builder — John Martinez
An operator — Sree Koneru
The vagus-nerve patent adds the fifth pillar:
A high-value, defensible therapeutic target producing rich physiological signals ideal for AI-driven closed-loop therapy.
This transforms ActiPatch from a static OTC device into:
A data node
A sensing hub
A closed-loop AI therapeutic engine
Exactly the architecture behind early AI unicorns — and exactly the kind of story that financial journalists elevate when a stock begins to run.
The BIEL Quantum Leap
BIEL is positioned to achieve in months what took Amazon, Netflix, Apple, Google, Tesla, Nvidia, etc., decades to accomplish.
If BIEL delivers $2.5M in net profit and convinces investors of sustainable, disruptive growth, it could theoretically command a $2.5B market cap (PPS = $0.10) — a 1000x P/E multiple driven by narrative momentum and valuation leverage. That mirrors Nvidia’s 100,000% run from its all-time low to all-time high.
The quantum leap depends on one thing:
Transforming investor perception.
If BIEL aligns profitability with a bold, disruptive vision (hello Electrome!), the market could reward it with exponential valuation leverage — turning a sub-penny stock into a medtech powerhouse.
BIEL already proved profitability is within reach:
Q3 2021 net income: $22,381 on $414,700 revenue, including $100k in COVID relief. This demonstrates how close the company is to sustained profitability given its ultra-lean operating model.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue.
Historical data suggests this is enough for consistent profitability.
Even the expectation of reaching $400k/qtr could push PPS to copper levels.
2. Reach $1.5M in annual revenue.
Confirms sustainable growth and strengthens investor confidence.
3. Leverage the new US distributor.
If investors value the partnership at even $300K, PPS exits the trips.
At $1M valuation, PPS hits copper.
Share Price Projection
Once profitability is achieved (or imminent), PPS is projected to hit copper ($0.01+).
For every additional $2.5M in annual profit, PPS could rise by $0.01 (P/E = 100).
Valuation Scenarios
>.001 PPS — Technical breakout (Golden Cross .0003, Blue-Sky .0006)
.003 PPS — 3,000% gain when US distributor news goes viral
.01 PPS — Profitability confirmed
.02 PPS — $5M profit
.04 PPS — $10M profit or $1M × 1000 P/E
.10 PPS — $25M profit or $2.5M × 1000 P/E
$1.00 PPS — After debt payoff + buyback
Tax Advantage: A Hidden Accelerator
BIEL holds a $40M tax-loss carryforward — meaning the first $40M in profits are tax-free.
This accelerates net profitability and preserves cash during early growth.
RecoveryRx: The High-Margin Engine
Post-op and wound-care device with doctor-ordered margins
Human + pet market = billions of potential monthly users
Veterinary version is a hidden goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life
ActiPatch as a Wellness Powerhouse
Off-label success across:
Menstrual pain
Migraines
Neuropathy
RLS
Opioid reduction
Bladder issues
Prostate health
BPH symptom relief
The Technical Indicators Are Primed
50 DMA: .0003
200 DMA: .0002
Golden Cross: .0003
Yearly High: .0005
Blue-Sky Breakout: .0006
Technicals attract chartists.
Fundamentals (news, PR) will follow.
With Fed rate cuts ahead, OTC stocks like BIEL are positioned to run like 2021.
The Big Picture: A Multi-Sector Bioelectric Platform
BIEL is positioned to dominate multiple billion-dollar verticals:
AI-driven bioelectric therapeutics
Chronic inflammation management
Non-invasive vagus nerve stimulation
Wearable health data ecosystems
Human OTC pain
Veterinary therapeutics
Subscription-based wellness platforms
This is not a penny-stock device company.
This is a public-market AI-bioelectric platform with asymmetric upside — and if the share price begins to climb, the financial press will seize the narrative, potentially making BIEL the story stock of 2026.
A rising stock price doesn’t just reward shareholders — it strengthens the company, accelerates the Electrome collaboration, attracts talent, unlocks capital, and amplifies the entire AI-bioelectric thesis.
This would be a 3,000% gain (from .0001 on Oct. 9, 2025) and exceed the PPS increase for Apple, Amazon, Netflix, Microsoft, Google, etc., for the past 10 years. We're already 13% of the way there. This will generate a huge amount of FREE PUBLICITY for BIEL/Electrome that would otherwise cost millions of dollars, launching world-wide sales. Big money will be knocking at the door, begging to buy in (MAKE THEM BUY SHARES ON THE OPEN MARKET INSTEAD!).
BIEL Will Become the First Public-Market Gateway Into AI-Driven Bioelectric Medicine
A Venture-Scale Opportunity With Public-Market Leverage
BIEL stands at the edge of a valuation supercycle — a moment where narrative, technology, and timing converge. In the same way Amazon, Netflix, Apple, and Nvidia transformed from overlooked microcaps into generational winners, BIEL now sits at the threshold of its own quantum leap. But unlike those giants, BIEL’s inflection point could unfold in weeks, not decades.
Public investors almost never gain early access to AI-platform upside.
BIEL + Electrome change that — and a rising BIEL share price amplifies everything: capital access, partnership leverage, and media visibility.
At a moment when AI narratives alone have minted billionaires, a fast-appreciating stock can turn BIEL from an overlooked microcap into the story stock of 2026, attracting institutional attention, analyst coverage, and nonstop financial-press momentum.
FDA deregulation of non-medical wearable data has recreated the same conditions that allowed early AI giants to explode in value — and the market loves that storyline.
The Core Thesis
BIEL has the hardware.
Electrome has the AI.
The new vagus-nerve patent provides the defensible therapeutic target.
The leadership team provides the execution engine.
Together, they form a platform-level company — not a device company — and a rising share price strengthens their ability to scale, recruit, and negotiate from a position of strength.
The Patent That Raises the Valuation Ceiling
Utility Patent Application 18/667,971 — Non-Invasive Vagus Nerve Stimulation (VNS)
Key Value Drivers
Non-invasive VNS using PEMF — no implants, no surgery.
Targets chronic inflammation affecting over one-third of Americans.
Applicable to arthritis, depression, diabetes, cardiovascular issues, autoimmune disorders.
Built on BIEL’s already-cleared PEMF platform — the fastest path to commercialization.
Invented by Martinez, McLeod, and Staelin — engineering + commercialization pedigree.
A rising stock price increases the perceived value of this IP, strengthens licensing leverage, and attracts strategic partners who follow momentum.
Why This Matters to Investors
VNS is one of the most valuable neuromodulation categories in medicine.
Existing players rely on implants — high cost, high friction, limited scale.
A non-invasive, wearable VNS device is a category-defining product with multi-billion-dollar potential.
And if the stock begins to move, financial media will spotlight BIEL as the first public-market play on AI-driven VNS — a narrative Wall Street loves.
How the Patent Supercharges the AI Narrative
To become an AI platform, BIEL needed four pieces:
A brain — Electrome
A story — Ken Mayer
A builder — John Martinez
An operator — Sree Koneru
The vagus-nerve patent adds the fifth pillar:
A high-value, defensible therapeutic target producing rich physiological signals ideal for AI-driven closed-loop therapy.
This transforms ActiPatch from a static OTC device into:
A data node
A sensing hub
A closed-loop AI therapeutic engine
Exactly the architecture behind early AI unicorns — and exactly the kind of story that financial journalists elevate when a stock begins to run.
The BIEL Quantum Leap
BIEL is positioned to achieve in months what took Amazon, Netflix, Apple, Google, Tesla, Nvidia, etc., decades to accomplish.
If BIEL delivers $2.5M in net profit and convinces investors of sustainable, disruptive growth, it could theoretically command a $2.5B market cap (PPS = $0.10) — a 1000x P/E multiple driven by narrative momentum and valuation leverage. That mirrors Nvidia’s 100,000% run from its all-time low to all-time high.
The quantum leap depends on one thing:
Transforming investor perception.
If BIEL aligns profitability with a bold, disruptive vision (hello Electrome!), the market could reward it with exponential valuation leverage — turning a sub-penny stock into a medtech powerhouse.
BIEL already proved profitability is within reach:
Q3 2021 net income: $22,381 on $414,700 revenue, including $100k in COVID relief. This demonstrates how close the company is to sustained profitability given its ultra-lean operating model.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue.
Historical data suggests this is enough for consistent profitability.
Even the expectation of reaching $400k/qtr could push PPS to copper levels.
2. Reach $1.5M in annual revenue.
Confirms sustainable growth and strengthens investor confidence.
3. Leverage the new US distributor.
If investors value the partnership at even $300K, PPS exits the trips.
At $1M valuation, PPS hits copper.
Share Price Projection
Once profitability is achieved (or imminent), PPS is projected to hit copper ($0.01+).
For every additional $2.5M in annual profit, PPS could rise by $0.01 (P/E = 100).
Valuation Scenarios
>.001 PPS — Technical breakout (Golden Cross .0003, Blue-Sky .0006)
.003 PPS — 3,000% gain when US distributor news goes viral
.01 PPS — Profitability confirmed
.02 PPS — $5M profit
.04 PPS — $10M profit or $1M × 1000 P/E
.10 PPS — $25M profit or $2.5M × 1000 P/E
$1.00 PPS — After debt payoff + buyback
Tax Advantage: A Hidden Accelerator
BIEL holds a $40M tax-loss carryforward — meaning the first $40M in profits are tax-free.
This accelerates net profitability and preserves cash during early growth.
RecoveryRx: The High-Margin Engine
Post-op and wound-care device with doctor-ordered margins
Human + pet market = billions of potential monthly users
Veterinary version is a hidden goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life
ActiPatch as a Wellness Powerhouse
Off-label success across:
Menstrual pain
Migraines
Neuropathy
RLS
Opioid reduction
Bladder issues
Prostate health
BPH symptom relief
The Technical Indicators Are Primed
50 DMA: .0003
200 DMA: .0002
Golden Cross: .0003
Yearly High: .0005
Blue-Sky Breakout: .0006
Technicals attract chartists.
Fundamentals (news, PR) will follow.
With Fed rate cuts ahead, OTC stocks like BIEL are positioned to run like 2021.
The Big Picture: A Multi-Sector Bioelectric Platform
BIEL is positioned to dominate multiple billion-dollar verticals:
AI-driven bioelectric therapeutics
Chronic inflammation management
Non-invasive vagus nerve stimulation
Wearable health data ecosystems
Human OTC pain
Veterinary therapeutics
Subscription-based wellness platforms
This is not a penny-stock device company.
This is a public-market AI-bioelectric platform with asymmetric upside — and if the share price begins to climb, the financial press will seize the narrative, potentially making BIEL the story stock of 2026.
A rising stock price doesn’t just reward shareholders — it strengthens the company, accelerates the Electrome collaboration, attracts talent, unlocks capital, and amplifies the entire AI-bioelectric thesis.
1
